CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

Arizona Tribune - CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that the CASI management team will participate at the Guggenheim Healthcare Innovation Conference 2025 in a fireside chat at 9:30 AM ET on November 12 in Boston, MA. CASI will also host one-on-one meetings with investors at the conference.

Text size:

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. and plans for first patient in first quarter of 2026. In parallel, CASI is actively recruiting and dosing patients in an ongoing Phase 1 study in immune thrombocytopenia (ITP). In addition, CASI is assessing multiple technologies for development of a stable, high concentration protein solution for subcutaneous injection.

More information on CASI is available at www.casipharmaceuticals.com.

INVESTOR CONTACT:

Ingrid Choong, PhD
650-619-6115
[email protected]

SOURCE: CASI Pharmaceuticals

View the original press release on ACCESS Newswire

E.Rodriguez--AT

RBGPF	-19.57%	69	$
RELX	-0.12%	33.3	$
NGG	-0.03%	90.29	$
VOD	-1.02%	15.69	$
RIO	1.15%	98.26	$
AZN	-0.47%	204.03	$
RYCEF	-1.59%	16.96	$
CMSC	0.18%	22.43	$
BTI	-0.07%	58.81	$
GSK	-0.26%	58.21	$
CMSD	0.18%	22.63	$
JRI	0.31%	13.02	$
BCC	-0.51%	80.17	$
BCE	-2.31%	23.35	$
BP	1.16%	46.44	$

Arizona Tribune - CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference

Featured

In fiery speech, Pope Leo says 'Enough to war!'

Benin leans into painful past to attract tourists

Panic buttons, undercover cops: How Peru bus drivers try to stay safe

Seniors Being Used As CBD Guinea Pigs In CMS Program?